Dissociation of vasospasm and secondary effects of experimental subarachnoid hemorrhage by clazosentan

Stroke

Volumn 42, Issue 5, 2011, Pages 1454-1460

  Sabri, Mohammed ^a   Ai, Jinglu ^a   MacDonald, R Loch ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

clazosentan; endothelin; mice; subarachnoid hemorrhage; vasospasm

Indexed keywords

CLAZOSENTAN; NITRIC OXIDE SYNTHASE; PEROXYNITRITE; SUPEROXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; MIDDLE CEREBRAL ARTERY; MOUSE; NERVE CELL LESION; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SUBARACHNOID HEMORRHAGE; THROMBOEMBOLISM; VASOSPASM;

ANIMALS; APOPTOSIS; DIOXANES; DISEASE MODELS, ANIMAL; MICE; MICE, TRANSGENIC; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; PYRIDINES; PYRIMIDINES; RECEPTOR, ENDOTHELIN A; REGIONAL BLOOD FLOW; SUBARACHNOID HEMORRHAGE; SULFONAMIDES; TETRAZOLES; THROMBOEMBOLISM; VASOSPASM, INTRACRANIAL;

EID: 79955465165     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.110.604728     Document Type: Article

References (21)

1. Lovelock CE, Rinkel GJ, Rothwell PM. Time trends in outcome of subarachnoid hemorrhage. Population-based study and systematic review. Neurology. 2010;74:1494-1501.
2. Macdonald RL, Pluta RM, Zhang JH. Cerebral vasospasm after subarach-noid hemorrhage: the emerging revolution. Nat Clin Pract Neurol. 2007; 3:256-263. (Pubitemid 46745473)
3. Pluta RM, Hansen-Schwartz J, Dreier J, Vajkoczy P, Macdonald RL, Nishizawa S, Kasuya H, Wellman G, Keller E, Zauner A, Dorsch N, Clark J, Ono S, Kiris T, Leroux P, Zhang JH. Cerebral vasospasm following subarachnoid hemorrhage: time for a new world of thought. Neurol Res. 2009;31:151-158.
4. Suzuki S, Kimura M, Souma M, Ohkima H, Shimizu T, Iwabuchi T. Cerebral microthrombosis in symptomatic cerebral vasospasm\a quanti-tative histological study in autopsy cases. Neurologia Medico-Chirurgica. 1990;30:309-316. (Pubitemid 20270142)
5. Dreier JP, Major S, Manning A, Woitzik J, Drenckhahn C, Steinbrink J, Tolias C, Oliveira-Ferreira AI, Fabricius M, Hartings JA, Vajkoczy P, Lauritzen M, Dirnagl U, Bohner G, Strong AJ. Cortical spreading ischaemia is a novel process involved in ischaemic damage in patients with aneurysmal subarachnoid haemorrhage. Brain. 2009;132: 1866-1881.
6. Stein SC, Browne KD, Chen XH, Smith DH, Graham DI. Thromboem-bolism and delayed cerebral ischemia after subarachnoid hemorrhage: an autopsy study. Neurosurgery. 2006;59:781-787. (Pubitemid 44579595)
7. Macdonald RL, Kassell NF, Mayer S, Ruefenacht D, Schmiedek P, Weidauer S, Frey A, Roux S, Pasqualin A. Clazosentan to Overcome Neurological Ischemia and Infarction Occurring After Subarachnoid Hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial. Stroke. 2008;39:3015-3021.
8. Kramer A, Fletcher J. Do endothelin-receptor antagonists prevent delayed neurological deficits and poor outcomes after aneurysmal subarachnoid hemorrhage? A meta-analysis. Stroke. 2009;40:3403-3406.
9. Bhardwaj A, Wu Y, Hurn PD, Kirsch JR, Traystman RJ. Administration of selective endothelin receptor type A antagonist Ro 61-1790 does not improve outcome in focal cerebral ischemia in cat. J Cereb Blood Flow Metab. 2000;20:499-504. (Pubitemid 30164894)
10. Roux S, Breu V, Giller T, Neidhart W, Ramuz H, Coassolo P, Clozel JP, Clozel M. Ro 61-1790, a new hydrosoluble endothelin antagonist: general pharmacology and effects on experimental cerebral vasospasm. J Pharmacol Exp Ther. 1997;283:1110-1118. (Pubitemid 28016483)
11. Sabri M, Jeon H, Ai J, Tariq A, Shang X, Chen G, Macdonald RL. Anterior circulation mouse model of subarachnoid hemorrhage. Brain Res. 2009;1295:179-185.
12. Sabri M, Ai J, Knight B, Tariq A, Jeon H, Shang X, Marsden PA, Loch Macdonald R. Uncoupling of endothelial nitric oxide synthase after experimental subarachnoid hemorrhage. J Cereb Blood Flow Metab 2011;31:190-199.
13. Teichert AM, Miller TL, Tai SC, Wang Y, Bei X, Robb GB, Phillips MJ, Marsden PA. In vivo expression profile of an endothelial nitric oxide synthase promoter-reporter transgene. Am J Physiol Heart Circ Physiol. 2000;278:H1352-H1361. (Pubitemid 30235515)
14. Hemmens B, Goessler W, Schmidt K, Mayer B. Role of bound zinc in dimer stabilization but not enzyme activity of neuronal nitric-oxide synthase. J Biol Chem. 2000;275:35786-35791.
15. Leber A, Hemmens B, Klosch B, Goessler W, Raber G, Mayer B, Schmidt K. Characterization of recombinant human endothelial nitric-oxide synthase purified from the yeast Pichia pastoris. J Biol Chem. 1999;274:37658-37664. (Pubitemid 30026823)
16. Paxinos G, Franklin KBJ. The Mouse Brain in Stereotaxic Coordinates, II ed. London: Academic Press; 2004.
17. Schubert GA, Schilling L, Thome C. Clazosentan, an endothelin receptor antagonist, prevents early hypoperfusion during the acute phase of massive experimental subarachnoid hemorrhage: a laser Doppler flow-metry study in rats. J Neurosurg. 2008;109:1134-1140.
18. Macdonald RL, Weir B. Cerebral Vasospasm. San Diego: Academic Press; 2001.
19. Ayer R, Zhang J. Connecting the early brain injury of aneurysmal sub-arachnoid hemorrhage to clinical practice. Turk Neurosurg. 2010;20: 159-166.
20. Dorhout Mees SM, van den Bergh WM, Algra A, Rinkel GJ. Antiplatelet therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev. 2007;4:CD006184.
21. Jang YG, Ilodigwe D, Macdonald RL. Metaanalysis oftirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2009;10:141-147